Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has proposed granting a general mandate to repurchase H shares, which will be put to a shareholder vote at an extraordinary general meeting scheduled for February 12, 2026. Shareholders are advised to consult their professional advisers regarding how to vote on the proposal.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260127-12002794), on January 27, 2026, and is solely responsible for the information contained therein.
Comments